Program
ulotaront
Also written as “SEP-363856”, “SEP-363856 75mg” and “SEP363856”.
Its studies are mostly in Schizophrenia · Generalized Anxiety Disorder · Depressive Disorder, Major · Parkinson Disease · Narcolepsy, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Otsuka | 265 open or running | phase 3since Aug 26, 2019 | Oct 24, 2013 | Mar 2028phase 3 · NCT07225712 |
| Sumitomo Pharma | 40 open or running | phase 3since Mar 29, 2021 | Nov 22, 2017 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 13 studies since Oct 24, 2013.
- Mar 29, 2021Phase 3 study in SchizophreniaSumitomo Pharma · NCT04825860 · 83 enrolled · China, Japan, Philippines and more
- Apr 26, 2021Phase 1 study in SchizophreniaOtsuka · NCT04865835 · 21 enrolled · United States
- Aug 10, 2021Phase 1 study in NarcolepsyOtsuka · NCT05015673 · 18 enrolled · United States
- Apr 27, 2022Phase 3 study in SchizophreniaSumitomo Pharma · NCT05359081 · 68 enrolled · Japan
- May 24, 2022Phase 1 study in SchizophreniaOtsuka · NCT05402111 · 31 enrolled · United States
- Jul 6, 2022Phase 1 study in SchizophreniaOtsuka · NCT05463770 · 15 enrolled · United States
- Aug 15, 2022Phase 1 study in SchizophreniaOtsuka · NCT05542264 · 19 enrolled · United States
- Oct 10, 2022Phase 2 study in Depressive Disorder, MajorOtsuka · NCT05593029 · 929 enrolled · United States, Bulgaria, Canada and more
- Nov 16, 2022Phase 3 study in SchizophreniaOtsuka · NCT05628103 · 101 enrolled · United States
- Feb 6, 20232 phase 3 studiesOtsuka · NCT05729373, NCT05741528
- Apr 27, 2023Phase 1 study in SchizophreniaOtsuka · NCT05848700 · 60 enrolled · United States
- Feb 27, 2025Phase 3 study in SchizophreniaOtsuka · NCT06894212 · 538 enrolled · United States, Japan
- Nov 5, 2025Phase 3 study in SchizophreniaOtsuka · NCT07225712 · 100 planned · Japan
- Aug 6, 20263 phase 3 studies in Generalized Anxiety DisorderOtsuka · NCT07759128, NCT07767903, NCT07786454
Ahead
- Mar 2028Primary completion: phase 3 study in SchizophreniaOtsuka · NCT07225712
- Oct 25, 2028Primary completion: phase 3 study in Generalized Anxiety DisorderOtsuka · NCT07767903
- Dec 6, 2028Primary completion: phase 3 study in Generalized Anxiety DisorderOtsuka · NCT07759128
- May 26, 2029Primary completion: phase 3 study in Generalized Anxiety DisorderOtsuka · NCT07786454
TargetBeta
“Serotonin 1a (5-HT1a) receptor agonist; Trace amine-associated receptor 1 agonist”ChEMBL 37, by rule
Studies
All 30 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07786454Generalized Anxiety Disorder · United States | 3 | Recruiting | Otsuka | May 26, 2029 | 1,120 |
| NCT07767903Generalized Anxiety Disorder · United States | 3 | Recruiting | Otsuka | Oct 25, 2028 | 384 |
| NCT07759128Generalized Anxiety Disorder · United States | 3 | Recruiting | Otsuka | Dec 6, 2028 | 576 |
| NCT07225712Schizophrenia · Japan | 3 | Recruiting | Otsuka | Mar 2028 | 100 |
| NCT06894212Schizophrenia · United States, Japan | 3 | Active, not recruiting | Otsuka | Oct 20, 2026 | 538 |
| NCT05848700Schizophrenia · United States | 1 | Completed | Otsuka | Mar 15, 2024 | 60 |
| NCT05741528Schizophrenia · United States | 3 | Completed | Otsuka | Sep 23, 2024 | 75 |
| NCT05729373Generalized Anxiety Disorder · United States, Bulgaria, Estonia and more | 3 | Completed | Otsuka | Sep 26, 2025 | 434 |
| NCT05628103Schizophrenia · United States | 3 | Completed | Otsuka | Apr 1, 2024 | 101 |
| NCT05593029Depressive Disorder, Major · United States, Bulgaria, Canada and more | 2 | Completed | Otsuka | Nov 6, 2025 | 929 |
| NCT05542264Schizophrenia · United States | 1 | Completed | Otsuka | Feb 12, 2024 | 19 |
| NCT05463770Schizophrenia · United States | 1 | Completed | Otsuka | Aug 22, 2023 | 15 |
| NCT05402111Schizophrenia · United States | 1 | Completed | Otsuka | Sep 27, 2023 | 31 |
| NCT05359081Schizophrenia · Japan | 3 | Terminated | Sumitomo Pharma | Mar 21, 2024 | 68 |
| NCT05015673Narcolepsy · United States | 1 | Completed | Otsuka | May 26, 2015 | 18 |
| NCT04865835Schizophrenia · United States | 1 | Completed | Otsuka | May 3, 2022 | 21 |
| NCT04825860Schizophrenia · China, Japan, Philippines and more | 3 | Terminated | Sumitomo Pharma | Oct 12, 2023 | 83 |
| NCT04369391Schizophrenia · United States | 1 | Completed | Otsuka | Nov 10, 2020 | 150 |
| NCT04325737Schizophrenia · Japan | 1 | Completed | Sumitomo Pharma | Aug 7, 2020 | 13 |
| NCT04115319Schizophrenia · United States, Romania, Russia and more | 3 | Completed | Otsuka | Dec 30, 2022 | 305 |
| NCT04109950Schizophrenia · United States, Bulgaria, Colombia and more | 3 | Terminated | Otsuka | Nov 9, 2023 | 463 |
| NCT04092686Schizophrenia · United States, Bulgaria, Croatia and more | 3 | Completed | Otsuka | Jun 14, 2023 | 464 |
| NCT04072354Schizophrenia · United States, Bulgaria, Colombia and more | 3 | Completed | Otsuka | May 12, 2023 | 463 |
| NCT04038957Schizophrenia · United Kingdom | 1 | Completed | Otsuka | Jun 6, 2023 | 22 |
| NCT03370640Schizophrenia · Japan | 1 | Completed | Sumitomo Pharma | Sep 20, 2018 | 24 |
| NCT02970929Schizophrenia · United States, Hungary, Romania and more | 2 | Completed | Otsuka | Jan 29, 2019 | 157 |
| NCT02969369Parkinson Disease Psychosis · United States | 2 | Completed | Otsuka | Apr 20, 2020 | 39 |
| NCT02969382Schizophrenia · United States, Hungary, Romania and more | 2 | Completed | Otsuka | Jul 31, 2018 | 245 |
| NCT01994473Schizophrenia · United States | 1 | Completed | Otsuka | Dec 2014 | 48 |
| NCT01972711Schizophrenia · United Kingdom | 1 | Completed | Otsuka | Jul 2015 | 105 |
How it is read
Names in the registry
- “SEP-363856”, 24 entries
- “SEP-363856 75mg”, 2 entries
- “SEP363856”, 2 entries
- “SEP-363856 100mg”, 1 entry
- “SEP-363856 50mg”, 1 entry
Conditions, from the studies’ own filings
- Schizophrenia, 23 studies
- Generalized Anxiety Disorder, 4 studies
- Depressive Disorder, Major, 1 study
- Parkinson Disease, 1 study
- Narcolepsy, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.